logo
Plus   Neg
Share
Email

AstraZeneca Plans To Conduct New Study Of BRILINTA In PAD Patients

AstraZeneca Plc (AZN,AZN.L) unveiled plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease, or PAD, a condition affecting approximately 27 million people in Europe and North America. PAD patients are at high risk of myocardial infarction, strokes, and other health complications.

EUCLID is designed to evaluate cardiovascular event rate and safety in PAD patients. BRILINTA (Ticagrelor) is currently not approved for the treatment of patients with PAD.

EUCLID is a randomized, double-blind, parallel group, multi-center study evaluating the efficacy of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) in reducing the primary endpoint - a composite of cardiovascular death, myocardial infarction or ischemic stroke - in patients with PAD.

In the EUCLID study, symptomatic PAD patients who are 50 years of age or older will be randomized to receive either ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily. Now that plans to initiate the study have been finalized, the EUCLID steering committee will begin the process of recruiting study investigators, clinical centers, and eventually patients.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Coca-Cola Company (KO) reported that its first-quarter comparable earnings per share from continuing operations grew 8% year-over-year to $0.47. On average, 20 analysts polled by Thomson Reuters expected the company to report profit per share of $0.46 for the quarter. Analysts' estimates typically... Eli Lilly and Co. (LLY) Tuesday reported a profit for its first-quarter, compared to a loss last year, primarily driven by higher operating income. Quarterly revenue increased 9 percent, driven primarily by the increased demand for new pharmaceutical products. The company raised its 2018 outlook. Both adjusted earnings per share and revenue for the quarter beat analysts' expectations. Shares of SAP SE were gaining around 3 percent in German trading after the software giant reported Tuesday higher first-quarter profit with strong growth in cloud subscriptions and support revenues. The company further lifted its outlook for fiscal 2018. CEO said, "With an increasing share of predictable revenues, our beyond expectations profitability is cause for even greater shareholder confiden
Follow RTT